Equity/Index & Cross Asset Volatility Specialist, Cameron Design

Jay Cameron

Equity/Index & Cross Asset Volatility Specialist

Cameron Design

We specialize in financial products and volatility. Our strategies balance speed, data, and risk control to capture opportunities across global markets. Our research leverages AI and data analytics to continuously refine our algorithms and adapt to evolving market dynamics.

Equity Derivatives

<ul>
<li>BillionToOne leverages its patented Quantitative Counting Technology (QCT) to achieve superior disease detection in molecular diagnostics, positioning the firm as a leader in prenatal  testing, carrier screening, oncology testing markets.</li>
<li>Demonstrating strong operational efficiency, BLLN achieved a 113% year-over-year revenue increase in 2024 and a 65% gross margin in the first half of 2025, suggesting a path to sustained profitability.</li>
<li>With a successful public debut, the recent price pullback, and an additional oncology pipeline slated for 2026, the company presents an intriguing opportunity for strategic long-term position building.</li>
</ul>


BillionToOne leverages its patented Quantitative Counting Technology (QCT) to achieve superior disease detection in molecular diagnostics, positioning the firm as a leader in prenatal  testing, carrier screening, oncology testing markets.
Demonstrating strong operational efficiency, BLLN achieved a 113% year-over-year revenue increase in 2024 and a 65% gross margin in the first half of 2025, suggesting a path to sustained profitability.
With a successful public debut, the recent price pullback, and an additional oncology pipeline slated for 2026, the company presents an intriguing opportunity for strategic long-term position building.


BillionToOne: More Than 60% Above IPO Pricing, What’s Ahead?

US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>BillionToOne priced above range at $60.00 and opened at $100.00, closing up 81.6% at $108.94.</li>
<li>The deal was more than 20x oversubscribed, driven by strong long-only and healthcare demand</li>
<li>Backed by top-tier investors and partnerships with Johnson &amp; Johnson, BLLN’s profitability and precision platform stood out in a choppy IPO market.</li>
</ul>


BillionToOne priced above range at $60.00 and opened at $100.00, closing up 81.6% at $108.94.
The deal was more than 20x oversubscribed, driven by strong long-only and healthcare demand
Backed by top-tier investors and partnerships with Johnson &amp; Johnson, BLLN’s profitability and precision platform stood out in a choppy IPO market.


BillionToOne, Inc. (BLLN): Precision Diagnostics Firm Soars 82% in One of 2025’s Best IPO Debuts

<ul>
<li>Single-Molecule precision enables highly accurate, scalable tests across prenatal and oncology diagnostics, setting BillionToOne apart from traditional sequencing-based competitors.</li>
<li>BillionToOne delivers 100%+ revenue growth, 69% gross margins, and positive EBITDA—rare performance metrics in molecular diagnostics ahead of its $2.3B IPO.</li>
<li>IPO is multiple-times oversubscribed with long-only healthcare anchors and top-tier backers, signaling strong institutional confidence ahead of pricing.</li>
</ul>


Single-Molecule precision enables highly accurate, scalable tests across prenatal and oncology diagnostics, setting BillionToOne apart from traditional sequencing-based competitors.
BillionToOne delivers 100%+ revenue growth, 69% gross margins, and positive EBITDA—rare performance metrics in molecular diagnostics ahead of its $2.3B IPO.
IPO is multiple-times oversubscribed with long-only healthcare anchors and top-tier backers, signaling strong institutional confidence ahead of pricing.


BillionToOne (BLLN) IPO: High-Growth Molecular Diagnostics Firm Captures Strong Investor Interest

<ul>
<li>BillionToOne (BLLN US) set terms for its IPO on October 17th by offering 3.846 million shares at $49-$55 and to debut on November 6th.</li>
<li>The underwriters have reserved up to 5% of the shares of Class A common stock through a directed share program. </li>
<li>There is a lot to like about this company including the explosive revenue growth and the narrowing losses.</li>
</ul>


BillionToOne (BLLN US) set terms for its IPO on October 17th by offering 3.846 million shares at $49-$55 and to debut on November 6th.
The underwriters have reserved up to 5% of the shares of Class A common stock through a directed share program. 
There is a lot to like about this company including the explosive revenue growth and the narrowing losses.


BillionToOne, Inc (BLLN): Precision Diagnostics Company Sets Terms, Seeking Up to $2.4b Valuation

Covering IPOs, Healthcare and Technology Stocks

Andrei Zakharov

<ul>
<li>BillionToOne Inc., a fastest-growing healthtech unicorn in the prenatal and oncology testing market in the U.S., set terms for its US IPO.</li>
<li>The California-based molecular diagnostics company posts hyper-growth and enjoys industry-leading gross margins. Positive non-GAAP op income is likely to be achieved in 2025.</li>
<li>BillionToOne Inc. has delivered 3+ years of exceptional revenue growth with a +167% CAGR over the past three years and strong gross margin profile supporting emerging profitability.</li>
</ul>


BillionToOne Inc., a fastest-growing healthtech unicorn in the prenatal and oncology testing market in the U.S., set terms for its US IPO.
The California-based molecular diagnostics company posts hyper-growth and enjoys industry-leading gross margins. Positive non-GAAP op income is likely to be achieved in 2025.
BillionToOne Inc. has delivered 3+ years of exceptional revenue growth with a +167% CAGR over the past three years and strong gross margin profile supporting emerging profitability.


BillionToOne IPO (BLLN.US): Unique Financial Profile For Molecular Diagnostics Company, Strong Buy

United States

BillionToOne, Inc. operates as a diagnostics company. The Company provides quantitative counting templates that detects genetic disorders in the developing baby from maternal blood, as well as invents in the patent-pending molecular counter platform, which increases the resolution of cell-free DNA detection. BillionToOne serves customers in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

BillionToOne (BLLN US)

BillionToOne: More Than 60% Above IPO Pricing, What’s Ahead?

BillionToOne's QCT technology leads in disease detection, showing momentum in revenue growth and potential for sustained profitability, making it...

Jay Cameron

BillionToOne, Inc. (BLLN): Precision Diagnostics Firm Soars 82% in One of 2025’s Best IPO Debuts

BillionToOne's successful IPO debut at $108.94 reflects strong demand from investors and partnerships with industry leaders like Johnson & Johnson.

IPO Boutique

BillionToOne (BLLN) IPO: High-Growth Molecular Diagnostics Firm Captures Strong Investor Interest

BillionToOne's single-molecule precision technology sets them apart in prenatal and oncology diagnostics, leading to impressive revenue growth and...

IPO Boutique

BillionToOne, Inc (BLLN): Precision Diagnostics Company Sets Terms, Seeking Up to $2.4b Valuation

BillionToOne sets terms for IPO, offering 3.846 million shares at $49-$55, with debut on November 6th and underwriters reserving up to 5% of...

IPO Boutique

BillionToOne IPO (BLLN.US): Unique Financial Profile For Molecular Diagnostics Company, Strong Buy

Healthtech unicorn BillionToOne Inc. sets terms for US IPO, showing hyper-growth and emerging profitability. In my insight, I discuss IPO...

Andrei Zakharov

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

BillionToOne: More Than 60% Above IPO Pricing, What’s Ahead?

​BillionToOne's QCT technology leads in disease detection, showing momentum in revenue growth and potential for sustained profitability, making it...

Jay Cameron

BillionToOne, Inc. (BLLN): Precision Diagnostics Firm Soars 82% in One of 2025’s Best IPO Debuts

​BillionToOne's successful IPO debut at $108.94 reflects strong demand from investors and partnerships with industry leaders like Johnson & Johnson.

IPO Boutique

BillionToOne (BLLN) IPO: High-Growth Molecular Diagnostics Firm Captures Strong Investor Interest

​BillionToOne's single-molecule precision technology sets them apart in prenatal and oncology diagnostics, leading to impressive revenue growth and...

IPO Boutique

BillionToOne, Inc (BLLN): Precision Diagnostics Company Sets Terms, Seeking Up to $2.4b Valuation

​BillionToOne sets terms for IPO, offering 3.846 million shares at $49-$55, with debut on November 6th and underwriters reserving up to 5% of...

IPO Boutique

BillionToOne IPO (BLLN.US): Unique Financial Profile For Molecular Diagnostics Company, Strong Buy

​Healthtech unicorn BillionToOne Inc. sets terms for US IPO, showing hyper-growth and emerging profitability. In my insight, I discuss IPO...

Andrei Zakharov

BillionToOne's QCT technology leads in disease detection, showing momentum in revenue growth and potential for sustained profitability, making it...

BillionToOne's successful IPO debut at $108.94 reflects strong demand from investors and partnerships with industry leaders like Johnson & Johnson.

BillionToOne's single-molecule precision technology sets them apart in prenatal and oncology diagnostics, leading to impressive revenue growth and...

BillionToOne sets terms for IPO, offering 3.846 million shares at $49-$55, with debut on November 6th and underwriters reserving up to 5% of...

Healthtech unicorn BillionToOne Inc. sets terms for US IPO, showing hyper-growth and emerging profitability. In my insight, I discuss IPO...